Citations 2
Utility of formalin-fixed, paraffin-embedded prostate biospecimens from low-resource settings for use in next-generation sequencing studies in African-descent populations
Kaninjing, Ernest , Adeniji, Kayode , Gachii, Andrew , Jibrin, Paul, Obafunwa, John , Ogo, Chidiebere, Faruk, Mohammed , Popoola, Ademola , Fatiregun, Omolara , Oluwole, Olabode P., Aiken, William , Roberts, Robin , Jyoti, Shravana Kumar, Dial, Chérif , Niang, Lamine, Ndoye, Médina , Karanam, Balasubramanyam , Francis, Damian , Gibbs, Denise , Brignole, Kathryn R. , Yates, Clayton , Ragin, Camille, Martin, Damali N. , Kaninjing, Ernest T , Mohammed, Faruk , Popoola, Ademola A , Fatiregun, Omolara , Jackson, Maria D. , Jalloh, Mohamed , White, Jason , Ragin, Camille
Journal of Global Health Reports | August 10, 2023 | Volume: 7 | Issue: No issue available | Pages: No page available
Background Men of African ancestry experience higher burden from prostate cancer compared to men of other ancestral backgrounds. Limitations in the availability of high-quality biospecimens hinder the inclusion of this population in genetic studies of prostate cancer. The use of formalin-fixed paraffin-embedded (FFPE) tissues represent a potential rich source of genetic material particularly in some international settings, where fresh frozen tissue is difficult to obtain. In this study, we investigate the feasibility of using FFPE biospecimens acquired from various international sites for utility in next-generation sequencing. Methods A total of 976 FFPE blocks were collected between 2002 and 2017 from six international sites in Africa and the Caribbean representing three consortia: Prostate Cancer Transatlantic Consortium; African-Caribbean Cancer Consortium; and Men of African Descent and Carcinoma of the Prostate. Genomic DNA was checked for quality and quantity. Differences in mean quality control (QC) for pre-and-post pathology training were assessed using t-test. Pearson chi-square with trend analysis examined association between time-category and QC success status. Association of continuous DNA quality (Q129/Q41 ratio) and time of specimen collection was estimated with linear regression. Samples with a DNA quantity >0.2µg and a Q129/Q41 ratio >0.00225 were submitted for whole exome sequencing (WES). Results There was a positive relative percentage change in DNA quantity from 2002 to 2017 for Jamaica, Kenya and Senegal. There was a decline in DNA quantity over the same time period for Nigeria. There was a statistically significant improvement in quality of samples from Kenya ( P =0.032), Nigeria ( P <.001) and Senegal ( P =0.043). There was a significant improvement in the collected DNA sample quality over time with an R 2 of 0.12. Conclusions FFPE samples from low-resource settings could potentially provide sufficient DNA for WES. Improvements in biospecimen collection processing and storage for research are needed in some of these settings.
IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer
Mucci, Lorelei A. , Vinson, Jacob, Gold, Theresa Margaret, Gerke, Travis , Filipenko, Julie, Green, Rebecca , Anderson, Simon , Badal, Simone , Bjartell, Anders , N., Kim , Davis, Ian D. , Enting, Deborah , Fay, André P. , Mateo, Joaquı́n , McDermott, Ray , Olmos, David , Omlin, Aurelius , Popoola, Ademola , Ragin, Camille , Roberts, Robin , Russnes, Kjell M. , Waihenya, Charles, Hyslop, Terry , Villanti, Paul , George, Daniel J. , Team, on behalf of the IRONMAN Global, Green, Rebecca M , Anderson, Simon G , Chi, Kim N , Mateo, Joaquin , McDermott, Ray , Odedina, Folakemi , Olmos, David , Omlin, Aurelius , Popoola, Ademola A , Ragin, Camille , Roberts, Robin , Stopsack, Konrad H , George, Daniel J , Lazarus, J. Michael , Stopsack, Konrad H. , Kantoff, Philip W. , Team, on behalf of the IRONMAN Global
JCO Global Oncology | November 4, 2022 | Volume: No volume available | Issue: 8 | Pages: No page available
PURPOSE To describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population. PATIENTS AND METHODS Initiated in 2017, IRONMAN (International Registry for Men with Advanced Prostate Cancer) is a prospective cohort of patients with advanced prostate cancer. The study will enroll 5,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC), recruited from Australia, the Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The study is collecting datatypes to study variation in care and treatment of advanced prostate cancer across countries and across academic, community-based, and government practices with a focus on clinical outcomes, patient-reported outcomes, epidemiologic data, biologic subtypes, and clinician questionnaires. RESULTS Through July 2022, 2,682 eligible patients were enrolled in 11 of 12 active countries. Sixty-six percent of patients have mHSPC, and 34% have CRPC. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five Veterans Affairs Medical Centers are enrolling patients. Globally, 23% of patients report being veterans of military service. CONCLUSION To our knowledge, this is the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. IRONMAN aims to identify optimal treatment sequences to improve survival, understand patient-reported outcomes, and explore novel biomarkers to understand treatment resistance mechanisms. Insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer.